Researchers developed the MK-801 bimodal drug that treats obesity, hyperglycemia, and dyslipidemia in mouse models by combining NMDA and GLP-1 receptor antagonism. The study found that inhibiting NMDA receptors can reduce weight and food consumption. MK-801, created using peptide cleavage and disulfide linker production, showed effective weight loss in rats and increased weight loss effectiveness when combined with GLP-1. The MK-801-GLP-1 conjugate successfully corrected obesity, diabetes, and dyslipidemia in rodent models. Further research is needed to explore the potential of this bimodal molecular strategy in clinical settings for safe and effective obesity management.
Source link
Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition
